<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04149860</url>
  </required_header>
  <id_info>
    <org_study_id>18146A</org_study_id>
    <nct_id>NCT04149860</nct_id>
  </id_info>
  <brief_title>Study With Lu AF87908 in Healthy Subjects and Patients With Alzheimer's Disease</brief_title>
  <official_title>Interventional, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AF87908 in Healthy Subjects and Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety of a single dose of Lu AF87908, how
      well it is tolerated and what the body does to the drug in healthy subjects and patients with
      Alzheimer's Disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be divided into three parts: Part A, Part B and Part C.

      Part A consists of up to 5 sequential cohorts (Cohorts A1 to A5):

      -Cohorts A1 to A5: 8 healthy subjects per cohort (aiming for an equal number of men and
      women): 6 randomized to Lu AF87908 and 2 randomized to placebo.

      Part B consists of up to 3 sequential cohorts (Cohorts B1 to B3):

      -Cohorts B1 to B3: 4 healthy Japanese and 4 healthy Chinese subjects per cohort: 6 subjects
      randomized to Lu AF87908 and 2 subjects randomized to placebo.

      Part C consists of up to 4 sequential cohorts (Cohort C1 to C4):

      -Cohort C1 to C4: 8 patients with Alzheimer's disease per cohort: 6 randomized to Lu AF87908
      and 2 randomized to placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent adverse events</measure>
    <time_frame>From Day 0 to Day 84</time_frame>
    <description>Safety and tolerability based on the safety assessments (clinical safety laboratory tests, vital signs, weight, ECG parameters and physical examination)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t) of Lu AF87908</measure>
    <time_frame>From Day 0 to Day 84</time_frame>
    <description>Area under the plasma concentration curve for Lu AF87908</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Lu AF87908</measure>
    <time_frame>From Day 0 to Day 84</time_frame>
    <description>Maximum observed plasma concentration for Lu AF87908</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax Lu AF87908</measure>
    <time_frame>From Day 0 to Day 84</time_frame>
    <description>Nominal time of occurence of Cmax of Lu AF97908 in plasma</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Healthy</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts A1-A5, 8 healthy subjects per cohort. Dose levels 1 - 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts B1-B3, 8 healthy Japanese and Chinese subjects per cohort. Dose levels 3 - 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts C1-C4, 8 subjects with Alzheimer's disease per cohort. Dose levels 3 - 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF87908</intervention_name>
    <description>Lu AF87908 concentrate for solution for infusion IV, single dose</description>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_label>Part C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>concentrate for solution for infusion IV</description>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_label>Part C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

        Healthy subjects:

        -Men and women ≥30 and ≤65 years of age with a body mass index (BMI) ≥18 and ≤32 kg/m2 and
        a minimum weight of 50 kg.

        Patients with Alzheimer's disease:

          -  Men and women with a clinical diagnosis of Alzheimer's disease, Stages 3-4 according
             to the FDA draft Guidance for Industry

          -  MMSE 20-30, AND

          -  CDR global score of 0.5 or 1.0.

          -  Confirmed or determined (via amyloid PET scan) to be amyloid positive.

          -  If on FDA approved Alzheimer's disease medication, the treatment has been stable for 4
             months prior to Day 1.

             -≥50 years of age

          -  BMI ≥18 and ≤34 kg/m2 and a minimum weight of 50 kg.

        Exclusion criteria

          -  Clinically relevant structural brain abnormality as assessed using MRI

          -  Any past or current treatment with an anti-Abeta or anti-tau active vaccine

          -  Any past or current treatment with a monoclonal antibody or anti-sense oligomer
             targeting tau within the last 6 months

          -  Treatment with influenza or pneumonia vaccine within the last 30 days prior to dosing
             of IMP

        Any other in- and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <phone>+45 36301311</phone>
    <email>LundbeckClinicalTrials@Lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>91206-4007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Email contact via H. Lundbeck A/S</last_name>
      <email>LundbeckClinicalTrials@Lundbeck.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 31, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2019</study_first_posted>
  <last_update_submitted>November 1, 2019</last_update_submitted>
  <last_update_submitted_qc>November 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

